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Abstract
Introduction We evaluated whether CK19, one of the main
cytoskeleton proteins of epithelial cells, is released as full-length
protein from viable tumor cells and whether this property is
relevant for metastatic progression in breast cancer patients.
Methods EPISPOT (EPithelial ImmunoSPOT) assays were
performed to analyze the release of full-length CK19 by
carcinoma cells of various origins, and the sequence of CK19
was analyzed with mass spectrometry. Additional functional
experiments with cycloheximide, Brefeldin A, or vincristine were
done to analyze the biology of the CK19-release. CK19-
EPISPOT was used to detect disseminated tumor cells in bone
marrow (BM) of 45 breast cancer patients who were then
followed up over a median of 6 years.
Results CK19 was expressed and released by colorectal (HT-
29, HCT116, Caco-2) and breast (MCF-7, SKBR3, and MDA-
MB-231) cancer cell lines. The CK19-EPISPOT was more
sensitive than the CK19-ELISA. Dual fluorescent EPISPOT with
antibodies against different CK19 epitopes showed the release
of the full-length CK19, which was confirmed by mass
spectrometry. Functional experiments indicated that CK19
release was an active process and not simply the consequence
of cell death. CK19-releasing cells (RCs) were detectable in BM
of 44% to 70% of breast cancer patients. This incidence and
the number of CK19-RCs were correlated to the presence of
overt metastases, and patients with CK19-RCs had a reduced
survival as compared with patients without these cells (P  =
0.025, log-rank test; P = 0.0019, hazard ratio, 4.7; multivariate
analysis).
Conclusions Full-length CK19 is released by viable epithelial
tumor cells, and CK19-RCs might constitute a biologically
active subset of breast cancer cells with high metastatic
properties.
Introduction
Cytokeratins (CKs) constitute the largest intermediate filament
protein subgroup and represent a multigene family with more
than 20 different types of polypeptides that are divided into
acidic type I (CK9-CK20) and basic type II (CK1-CK8) kerat-
ins [1]. Cells of normal epithelium express at least one type I
and one type II keratin. CKs form the cytoskeleton of epithelial
cells, and their main function is to maintain the epithelial cell
integrity. However, other functions include roles in cell signal-
ing, stress responses, and apoptosis [2]. CKs undergo a com-
plex regulation involving post-translational modifications and
interactions with self and with various classes of associated
BM: bone marrow; CK: cytokeratin; DTCs: disseminated tumor cells; EPISPOT: epithelial immunospot; FC: flow cytometry; FCS: fetal calf serum; 
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proteins [2]. During apoptosis, epithelial cells are targets of
caspase-mediated proteolysis [3]. CK19, one of the three
main keratins besides CK8 and CK18 expressed in simple or
stratified epithelium and in various carcinomas including
breast cancer [4], is cleaved by caspase 3, and the soluble
fragments are released and detected in cancer patients [5]. In
contrast, the release of intact, nondegraded CK molecules has
not yet been demonstrated.
Bone marrow (BM) is the common homing site for dissemi-
nated tumor cells (DTCs) in patients with epithelial tumors and
the predominant site of overt metastasis in breast cancer [6].
However, the survival analysis of large cohorts of breast can-
cer patients [7] and further immunophenotyping of DTCs has
indicated that only a subset of DTCs might be relevant for met-
astatic relapse [6]. Thus, the characterization of the biologic
properties of DTCs is of utmost importance. Interestingly,
CK19 expression is the most common single marker used for
the RT-PCR-based detection of DTCs in the BM of breast can-
cer patients, and the detection of DTCs expressing this partic-
ular cytokeratin is correlated to an unfavorable prognosis
because of metastatic relapse [6]. It can therefore be specu-
lated that CK19 not only is a marker for epithelial tumor cells
but also may have some biologically relevant functions in early
metastatic spread. In view of the recent hypothesis on the role
of cancer stem cells in metastatic spread [6], it also is interest-
ing that CK19 has been suggested as a potential breast stem/
progenitor cell marker [8-10]. Thus, it can be speculated that
CK19-positive tumor cells might be an important subset of
breast cancer cells.
The present investigation is an extension of our initial work
[11], including now as novel findings (a) the proof that full-
length CK19 is released by cancer cells, (b) detailed clinical
data on the cancer patients, and (c) most important, clinical
follow-up information including multivariate analysis. Our data
suggest that the presence of CK19-releasing tumor cells in
BM of breast cancer patients is linked to metastatic progres-
sion. This discovery may contribute to a better understanding
of the heterogeneous biologic potential of DTCs in breast can-
cer patients.
Materials and methods
Cell lines
Colorectal (HT-29-ATCC: HTB-38; CaCo-2-ATCC: HTB-37;
HCT116-ATCC: CCL-247) and mammary (MCF-7-ATCC:
HTB-22; SKBR3-ATCC: HTB-30; MDA-MB-231-ATCC: TB-
26) adenocarcinoma cell lines were used for the optimization
of the CK19-EPISPOT. Head and neck squamous cancer cell
lines (SCC-14C/SCC-22A) were kindly provided by Prof.
Brakenhoff (Department Otolaryngology, Amsterdam, The
Netherlands). ML-1 and C643 thyroïd cancer cell lines were
kindly provided by Dr. Grimm (Department of Nuclear Medi-
cine, Regensburg University, Germany) and Dr. Heldin
(Department of Genetics and Pathology, Uppsala University
Hospital, Uppsala, Sweden), respectively.
HT-29 and HCT 116 cells were maintained in McCoy's 5A
medium (Invitrogen, Leiden, The Netherlands); CaCo-2 and
C643 cells, in minimal essential medium (Eurobio); and MCF-
7, SKBR3, MDA-MB-231, ML-1, SCC-14C, and SCC-22A
cells, in Dulbecco's modified Eagle's medium (DMEM; Bio-
chrom KG, Berlin, Germany). These media were supple-
mented with 1% L-glutamine (GlutaMax; Life Technologies,
Paisley, Scotland), 10% fetal calf serum (FCS; Life Technolo-
gies), 500 U/ml penicillin and 500 μg/ml streptomycin (Life
Technologies).
Patients and healthy controls
As shown in Table 1, 45 breast cancer patients (median age,
49 years; range, 31–66 years) at different stages (20 stage IV
patients with overt metastases and 25 patients with apparently
localized disease: stage I, one patient; stage III, 19 patients;
inflammatory cancer, 5 patients) were included at the Val
d'Aurelle Centre (Montpellier), as well as 11 patients with a
lymphoma as the negative control group. All breast cancer
patients included in this study (from 1996 through 1998) were
participating in a therapeutic trial with the agreement of the
local bioethics committee, and BM aspirates were taken at the
time of diagnosis of their breast cancer. Concerning the con-
trol group, the BM aspirates were taken for the diagnosis of
their lymphoma. Written informed consent was obtained from
all patients. All 25 breast cancer patients with apparently local-
ized disease were included after surgery but before any sys-
temic treatment (e.g., radiotherapy/chemotherapy). BM
aspiration in the 20 patients with metastatic cancer was per-
formed before and after initiation of systemic therapy (9 and
11 patients, respectively).
Preparation of BM
BM was aspirated from the upper iliac crest, and mononuclear
cells were isolated with Ficoll-density centrifugation, as
described previously [12]. Cells derived from BM samples
were then cryopreserved in liquid nitrogen before the CK19-
EPISPOT.
CYFR 21-1 measurement
CYFRA 21-1 was measured with the CYFRA 21-1 immuno-
metric assay (B.R.A.H.M.S., Hennigsdorf, Germany) in culture
supernatants (Tables 2 and 3).
EPISPOT assays
The EPISPOT was performed as previously described [13].
For the CK19-EPISPOT, the anti-CK19 Ks19.1 (6 μg/ml) and
the Alexa488-conjugated anti-CK19 Ks19.2 (3 μg/ml) mAbs
(Progen Biotechnik GMBH, Heidelberg, PA) and/or and the
Alexa555-conjugated anti-CK19 mAb AE1 (3 μg/ml) (Chemi-
con International, Temecula, CA) were used.Available online http://breast-cancer-research.com/content/11/3/R39
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For the dual-fluorescent CK19/MUC1-EPISPOT, a mixture of
anti-CK19 mAb Ks19.1 and anti-MUC1 mAb 115D8 (5 μg/ml)
(Centocor, Malvern, PA) with a mixture of Alexa488-conjugated
anti-CK19 mAb Ks19.2 and Alexa555-conjugated anti-MUC1
mAb DF3 (1:3,000) (Centocor) were used.
CK19-EPISPOT with Brefeldin A was performed to study the
CK19 intracellular transport. Brefeldin A (3 μg/ml) was added
in the culture medium of MCF-7 cells during the 24-hour cell-
incubation step of the EPISPOT.
Flow-cytometry experiments
The expression of CK19 in cancer cell lines (HT-29, HCT-116,
CaCo2, MCF-7, SKBR3, MDA-MB-231, SSC-14C, SSC-
22A, ML1, and C643) was determined with flow cytometry
(FC 500 apparatus; Beckman-Coulter, Villepinte, France)
(Table 2). Intracytoplasmic CK19 staining was performed by
using the Alexa488- or Alexa555-conjugated anti-human CK19-
Ks19.2 mAb (Progen Biotechnik), and the IntraPrep permea-
bilization reagent kit (Beckman-Coulter).
Immunocytochemistry
Cell lines were immunostained with Alexa488-conjugated anti-
CK19 mAb, as described earlier for the flow cytometry (Table
2). Then cells were seeded on glass slides, which were
mounted in ProLong Gold antifade reagent with DAPI (Invitro-
gen) and analyzed (Axio Imager M1, Carl Zeiss Vision, Halber-
moos, Germany).
MCF-7 cells were incubated with vincristine, 20 μmol/l
(Sigma-Aldrich, Steinheim, Germany), an inducer of apopto-
sis, and immunostained by using the M30 CytoDEATH Fluo-
rescein (Peviva, Bromma, Sweden) and the Alexa555-
conjugated anti-CK19 mAb Ks19.2.
A dual immunostaining was performed on MCF-7 cells by
using the Alexa488-conjugated anti-CK19 mAb Ks19.2 and the
Alexa555-conjugated anti-MUC1 mAb DF3. Nuclear counter-
staining was performed with DAPI.
Western blot
To detect the expression of CK19 protein in the cell lines
(MCF-7, SSC-14C, SSC-12A, and C643; Table 2), cells were
lysed in Triton-DOC lysis buffer. After centrifugation, superna-
tants were collected and analyzed with Western blotting. Sam-
ples were mixed with an equal volume of 2 × Laemmli buffer,
boiled (5 min), and then loaded onto a 12% polyacrylamide
gel. Proteins were electroblotted onto Immobilon membranes,
and CK19 was detected by using the Alexa488-conjugated
anti-CK19 KS 19.2 mAb. The Immobilon membrane was
scanned by using a Typhoon model 8600 phosphorimager
with ImageQuant software (Molecular Dynamics, Sunnyvale,
CA).
Mass spectrometry and protein identification
MCF-7 and C643 cells were cultured in FCS-free medium and
tested with the EPISPOT to confirm that full-length CK19 still
could be detected. FCS-free medium was used as negative
control. Five milliliters of each cell-culture supernatant was
concentrated by using 5-kDa cut-off centrifugal filter units (Mil-
lipore). The concentrated supernatants were diluted with 50
mmol/l ammonium bicarbonate in a volume of 50 μl and
digested with 1 μg trypsin at 37°C. Hydrophobic proteins
Table 1
Patient characteristics
Variable Patients (n = 45)
Number (%)
Age
<50 years 25 (55.6)
≥50 years 20 (44.4)
Tumor status
pT1 9 (20)
pT2 19 (42.2)
pT3 5 (11.1)
pT4 11 (24.5)
pTx 1 (2.2)
Lymph node status
pN0 4 (8.9)
pN1 41 (91.1)
Metastasis
M0 20 (44.4)
M1 25 (55.6)
Grade
12  ( 4 . 4 )
2 17 (37.8)
3 23 (51.1)
Unknown 3 (6.7)
Estrogen-receptor and progesterone status
ER+ 25 (56.8)
ER- 19 (43.2)
PR+ 21 (47.7)
PR- 23 (52.3)Breast Cancer Research    Vol 11 No 3    Alix-Panabières et al.
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attached to the centrifugal filter unit were digested with 1 μg
trypsin in 50 μl 10% (vol/vol) acetonitril in 50 mmol/l ammo-
nium bicarbonate at 37°C. Samples were cleaned of salts by
using STAGE tips [14].
Nanoscale LC-MS/MS was performed by coupling an Agilent
1100 Series LC system to a LTQ XL quadrupole ion-trap mass
spectrometer (Finnigan, San Jose, CA), as described earlier
[15].
Statistical analysis
Kaplan-Meier life-table curves were used to visualize for overall
survival. The log-rank test was used to compare significance of
differences between the curves.
Cox's proportional hazards regression model with a stepwise
selection procedure was applied to investigate main prognos-
tic factors. Hazards ratios with 95% CIs were presented to
display modifications in the risk of death.
All statistical tests were two-sided, and a P value of less than
0.05 was considered statistically significant. Statistical analy-
Table 2
Detection of CK19 in cancer cell lines by different methods
Colorectal cells Breast cells Head/Neck cells Thyroid cells
HT29 HCT116 Caco-2 MCF7 14C 22A ML1 C643
Detection of intracellular CK19
FC + + + + - - - -
ICC + + + + - - - -
WB ND ND ND + - - ND -
Detection of released CK19
EPISPOT + + + + - - - -
ELISA + + + + - - - -
CK19 detection. FC = flow cytometry; ICC = immunocytochemistry; WB = Western blot; ND = not determined; EPISPOT = EPithelial 
ImmunoSPOT assay; ELISA = CYFRA 21-1 immunometric assay (B.R.A.H.M.S.).
Table 3
Comparative sensitivity of two immunometric assays for detection of released CK19 in cancer cells
Cells/well HT-29 cells HCT 116 cells Caco-2 cells MCF-7 cells
EPISPOT ASSAY
1,000 212.5 ± 32.7
(21.3%)
867.0 ± 28.4
(86.7%)
600.0 ± 56.5
(60.0%)
113.3 ± 4.7
(11.4%)
100 19.8 ± 3.3
(19.8%)
93.0 ± 3.0
(93.0%)
67.5 ± 7.0
(67.5%)
13.5 ± 2.1
(13.5%)
10 2.0 ± 0
(20.0%)
7.3 ± 1.8
(73.0%)
5.5 ± 0.5
(55.0%)
2.0 ± 0.7
(20.0%)
1 0.25 ± 0.38
(25.0%)
1.0 ± 0
(100.0%)
0.4 ± 0.5
(40.0%)
0.23 ± 0.94
(23.0%)
ELISA
1,000 2.1 ± 3.0 12.0 ± 9.2 16.7 ± 2.9 16.2 ± 5.2
100 0.2 ± 0.2 1.0 ± 1.4 1.5 ± 1.8 2.6 ± 0.7
10 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0
1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0
EPISPOT and ELISA assays. Cells were cultured for 24 hours on nitrocellulose membranes of the Elispot plates. For the EPISPOT, values are 
expressed asCK19-releasing cells per well (mean ± SD of three experiments, with two wells in each experiment). Supernatants of the cultured 
cells were tested by the CYFRA 21-1 immunometric assay, and results are expressed as nanograms per milliliter.Available online http://breast-cancer-research.com/content/11/3/R39
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ses were performed by using the SAS v9 software (SAS Insti-
tute, Cary, NC).
Results
Release of CK19 by cancer cells
To evaluate whether epithelial tumor cells can release the
CK19 protein, we applied two immunometric assays (ELISA
and EPISPOT) to a panel of different cancer cell lines (Table
2). The ELISA detected an epitope on the CYFRA 21-1 part of
CK19 in the cell-culture supernatants, whereas the
CK19(Alexa488)-EPISPOT (Figure 1a), an adaptation of the Elis-
pot technique, detects fingerprints of the CK19 protein
secreted by single epithelial cells on a solid membrane [13].
Green fluorescent immunospots correspond to viable CK19-
releasing cells (RCs).
For the CK19-EPISPOT, two mouse monoclonal anti-CK19
antibodies, clones Ks19.1 (specific for the amino acids 311 to
335) and Ks19.2 (specific for the amino acids 346 to 368),
recognizing both epitopes on the CYFRA 21-1 fragment, were
used (Figure 1b). The antibodies used in both immunometric
assays were not able to distinguish the soluble fragment
CYFRA 21-1 and the full length of CK19. In parallel, we
assessed the intracellular expression of CK19 protein with
flow cytometry, immunocytochemistry (ICC), and Western blot
experiments. CK19 expression and release were detected in
colon and breast cancer cell lines but not in the head and neck
squamous and thyroid cancer cell lines analyzed (Table 2). The
lack of CK19 expression in the two head and neck cancer cell
lines is of interest, given the reported impact of CYFRA 21-1
measurements in this disease [16]. Thus, it can be speculated
that CK fragments found in the blood of head and neck cancer
patients might not be the results of active release but rather
reflect apoptotic or necrotic processes.
We determined the sensitivity of the CK19-EPISPOT in com-
parison to the CYFRA 21-1 ELISA by using the same antibody
clones in both immunometric assays. Serial dilutions of the HT-
29, HCT 116, Caco-2, and MCF-7 cell lines were tested
(Table 3). CK19-EPISPOT was able to detect tumor cells even
at the lowest concentration (1 cell/well), whereas at least 100
cells were needed to obtain a positive ELISA signal, indicating
a two-orders-of-magnitude greater sensitivity of the EPISPOT.
Taken together, these results indicate that the CK19-EPIS-
POT permitted the enumeration of very small numbers of
CK19-RCs.
Release of the full-length CK19 protein by cancer cells
Several groups demonstrated that the release of CYFRA 21-1
occurs when CK19 is cleaved by caspase 3 during apoptosis
[3,17]. However, it is still debated whether MCF-7 cells
expresses caspase 3 [18]. Other caspases (e.g., caspase 7
and 9) can cleave cytokeratins in a similar manner, and these
caspases might be active in MCF-7 cells lacking caspase 3
[18].
To demonstrate that the CK19 protein released by the cancer
cells analyzed was the intact full-length CK19 protein and not
its soluble fragment, we developed a dual-fluorescent CK19-
EPISPOT that is able to distinguish both peptides (i.e., the full
length CK19 and the CYFRA 21-1). Thus, for the coating step,
the same anti-CK19 antibody Ks19.1 that recognizes an
epitope on the CYFRA 21-1 fragment of the CK19 (amino
acids 311 to 335) (Figure 1b) was used. For the revelation
step, we used monoclonal antibody Ks19.2 recognizing CK19
Figure 1
Detection of CK19 protein Detection of CK19 protein. (a) CK19-EPISPOT assay procedure. Day 
1: The membranes of the ELISPOT plates are coated with an anti-
human CK19 monoclonal antibody (mAb, Ks19.1). Days 2 to 3: Next, 
the cells are seeded in each well and cultured for 48 hours. During this 
incubation period, the released specific proteins are directly immuno-
captured by the immobilized mAb on the bottom of the well. Plates are 
then washed, and cells are removed. The presence of the released 
CK19 protein is revealed by the addition of an anti-human CK19 mAb 
(Ks19.2) conjugated with a fluorochrome. Day 4: Fluorescent immunos-
pots are counted with an automated reader. One immunospot corre-
sponds to the fingerprint left only by one viable releasing epithelial 
tumor cell. (b) Schematic representation of the assumed binding sites 
of anti-cytokeratin antibodies and cleavage site for caspase 3 on the 
human CK19 protein [3,40].Breast Cancer Research    Vol 11 No 3    Alix-Panabières et al.
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at the amino acids 346 to 368 and monoclonal antibody AE1
recognizing CK19 on a different epitope, localized on the
other side of the cut site of the caspase 3 at the amino acids
145 to 227 (Figure 1b). Ks19.2 and AE1 were conjugated
with two different fluorochromes (i.e., Alexa488 and Alexa555,
respectively). By using this dual-fluorescent CK19(Alexa488)/
CK19(Alexa555)-EPISPOT on MCF-7 breast cancer cells only
dual(yellow) immunospots were observed (Figure 2a), indicating
that all cells released the intact full-length CK19 protein. Sim-
ilar results were obtained with the two other breast cancer cell
lines, SKBR3 and MDA-MB-231 (data not shown).
In addition, the release of full-length CK19 protein (400 amino
acids) by MCF-7 cells was investigated with peptide sequenc-
ing by using nanoscale reversed-phase liquid chromatography
tandem mass spectrometry (LC MS/MS analysis) (data not
shown). Peptides were detected ranging from CK19 amino
acids 8 to 398, which demonstrated that the full-length CK19
was present in the cell-free supernatant. Importantly, the tryp-
tic peptide 'GQVGGQVSVEVDSAPGTDLAK' (amino acids
227 to 247), which can emerge only from the entire CK19 pro-
tein, was detected (data not shown).
Active release of CK19 by viable cancer cells
It has been reported that the CK19 is released by apoptotic or
necrotic cells [19,20]. We reversely inhibited translation by
incubation of the cells with cycloheximide to analyze whether
CK19 release is an active process that requires protein trans-
lation. The addition of cycloheximide to cell cultures before
and during the incubation step of the CK19-EPISPOT led to a
decrease in the size and the number of CK19 spots or even
their disappearance, confirming that the de novo synthesis of
the CK19 protein by viable epithelial cancer cells is required
for the active release of CK19 (Figure 2b). Moreover, to study
the CK19-release pathway, we inhibited the protein transport
in the Golgi apparatus by incubation of the cells with the lac-
tone antibiotic, Brefeldin A. The addition of Brefeldin A to cell
culture during the CK19-EPISPOT did not affect the CK19
release, demonstrating that the CK19 protein is not in transit
through the endoplasmic reticulum or the Golgi apparatus
(data not shown).
MUC1 is another specific tumor-associated marker that has
been already used for the detection of disseminating tumor
cells [21,22]. We previously showed that the release of MUC1
is restricted to viable tumor cells (e.g., MCF-7) [13]. We there-
fore optimized a dual-fluorescent MUC1(Alexa555)/
CK19(Alexa488)-EPISPOT to verify whether these cells were
able to release both proteins simultaneously. We observed
that a majority of the immunospots obtained after 24 hours of
cell culture were yellow, resulting from an equivalent mixture of
the released MUC1 and CK19 proteins and confirming that
these cells were viable cells able to neosynthetize and actively
release in vitro MUC1 and CK19 (Figure 2c). In additional ICC
experiments, we showed that MCF-7 cells with an intact
Figure 2
EPISPOT assays and immunocytochemistry experiments EPISPOT assays and immunocytochemistry experiments. (a) Dual-fluo-
rescent CK19-EPISPOT assay with two different couples of mAbs. 
Red and green immunospots represent protein fingerprints of cells 
releasing CK19 detected with anti-CK19 AE1Alexa555 and Ks19.2Alexa488 
mAbs, respectively. Yellow fluorescent immunospots (Merge) are the 
results of dual staining with both mAbs. (b) Single-fluorescent CK19 
Ks19.2(Alexa488)-EPISPOT assay on MCF-7 cells without and with the 
addition of cycloheximide (50 μg/ml). (c) Dual-fluorescent CK19 
Ks19.2(Alexa488)/MUC1(Alexa555) EPISPOT assay on the MCF-7 cancer 
cell line. Green and red immunospots represent CK19-RCs and 
MUC1-RCs, respectively. Yellow fluorescent immunospots (Merge) are 
the results of dual staining with both mAbs. (d) Immunostaining of the 
nucleus(dapi), the MUC1(Alexa555), and the CK19 Ks19.2(Alexa488) of breast 
MCF-7 cells (left). Immunostaining of the nucleus(dapi), the CK19 
Ks19.2(Alexa555), and the cleaved cytokeratin 18 with the M30 CytoDE-
ATH(FITC)of MCF-7 cells after an incubation with vincristine (20 μmol/l), 
an inducer of apoptosis (right). The antibody M30 CytoDEATH which 
recognizes a neo-epitope formed after caspase cleavage of cytokeratin 
18 at Asp396 (CK18Asp396-NE M30 neo-epitope) during and after 
apoptosis, does not bind native CK18 of normal cells and is a very reli-
able and convenient tool for demonstration of apoptosis in single cells 
[41]. CK19 vesicles were detectable in the viable but not in the apop-
totic MCF-7 cells.Available online http://breast-cancer-research.com/content/11/3/R39
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nucleus (DAPI staining) contained CK19 vesicles with a
peripheral MUC1 expression at the cell membrane (Figure 2d).
Induction of apoptosis with vincristine and green staining of
apoptotic cells showed that these CK19 vesicles were detect-
able only in the subset of nonapoptotic MCF-7 cells (Figure
2d).
CK19-releasing cells in BM of breast cancer patients
The detection and characterization of DTCs in the BM of
patients with solid epithelial tumors is an emerging clinical
research field, in particular in breast cancer patients [23].
Recently, we demonstrated the presence of CK19-RCs, even
in the absence of overt metastases (stage M0), indicating clin-
ically occult homing of viable cancer cells in BM [11]. Here, we
confirmed the specificity of the CK19-EPISPOT by demon-
strating consistently negative findings in 11 BM samples from
control patients (data not shown).
The main purpose of the present study was to obtain informa-
tion on the prognostic relevance of CK19-RCs. Breast cancer
patients were followed up for a median period of 6 years, and
comparison of survival distribution with Kaplan-Meier analysis
by using the log-rank test was performed. The clinical informa-
tion on the patients is shown in Table 1. Most patients were in
an advanced disease stage. Of the 25 M0-patients (55.5%), 6
patients were free of lymph-node metastases, whereas the
remaining 19 patients already had histologically detectable
nodal metastasis. Twenty (44.5%) M1 patients had overt dis-
tant metastases localized in BM/liver (n = 6), BM (n = 3), lung
(n = 3), liver (n = 2), BM/lung (n = 2), lung/liver (n = 1), liver/
brain (n = 1), skin (n = 1), and BM/liver/lung (n = 1). Among
45 breast cancer patients, 19 experienced disease recur-
rence: local relapses were diagnosed in two (4.5%) patients,
and new distant metastases were diagnosed in 17 (38%)
patients in the liver (n = 4), BM (n = 4), lung (n = 3), BM/brain
(n = 2), mediastinum (n = 1), skin/lung (n = 1), skin (n = 1),
bone/meningitis (n = 1), and pleura (n = 1). Twenty-nine
(64.5%) deaths were reported.
All M0 patients received an anthracycline-based chemotherapy
regimen. Considering the bad prognosis of the patients with
massive lymph node involvement, 8 patients received, in addi-
tion, a high dose of chemotherapy with autologous bone mar-
row transplantation, and 5 patients received a sequential
association of anthracycline and docetaxel. Nearly all patients
(except for two) with hormone receptor-positive tumors
received adjuvant tamoxifen therapy.
All M1 patients received a chemotherapeutic treatment after
the bone marrow sampling. Considering the heterogeneity of
settings of this population, the numerous chemotherapeutic
regimens (e.g., four cycles of the FAC65 regimen, seven
cycles of a sequential association AC65-docetaxel, four
cycles of an FEC100 regimen, and then autologous bone mar-
row transplantation) are not reported here in detail.
The enumeration CK19-RCs and MUC1-RCs allowed the
detection of viable DTC in 44% and 48% of M0 patients,
respectively, whereas the corresponding detection rates were
70% and 65% in M1 patients, respectively. If the results of
both CK19- and MUC1-RC measurements were combined, it
showed that viable DTCs were present in 56% and 90% of M0
patients and M1 patients, respectively. The number of DTCs
was significantly higher (P = 0.01) in the M1 patients (CK19-
RCs: median, 7; range, 0 to 758; MUC1-RCs: median, 10;
range, 0 to 812) compared with the M0 patients (CK19-RCs:
median, 0; range, 0 to 254; MUC1-RCs: median, 0; range, 0
to 32).
We calculated the Kaplan-Meier curves for patients, depend-
ing on the presence or absence of either CK19-RCs or
MUC1-RCs. As shown in Figure 3a, the detection of CK19-
Figure 3
Survival data Survival data. Kaplan – Meier estimates of cancer-related survival of 
breast cancer patients, according to the presence or absence of viable 
CK19-RCs. (a), MUC1-RCs (b), and subpopulations of cells 
CK19+MUC1-, CK19+MUC1+ (c) in the BM. RCs = releasing cells.Breast Cancer Research    Vol 11 No 3    Alix-Panabières et al.
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RC was prognostically relevant (P = 0.0067); no obvious dif-
ference was noted in the sites of metastasis between patients
with and without CK19-RCs. In contrast, the detection of
MUC1-RCs had no prognostic impact (P = 0.6106; Figure
3b).
We also calculated the Kaplan-Meier curves for the three sub-
sets CK19-, CK19+MUC1+, and CK19+MUC1- (Figure 3c).
Because of the low number of cases, the P value (P = 0.1027)
did not reach statistical significance, but the results showed
that breast cancer patients harboring the subset of
CK19+MUC1- DTC had the worse survival curve.
Subsequently, multivariate analysis was performed, taking the
most important variables into account. Type of therapy was
strongly linked to TNM stage and was therefore not consid-
ered an independent variable. As shown in Table 4, the pres-
ence of CK19-RCs was the strongest prognostic predictor,
with a hazard ratio of 4.7 and a P value of 0.0019. Because of
the limited number of patients, the nature of the multivariate is,
however, rather exploratory.
Discussion
In contrast to the common concept that cytokeratins are
released in fragmented forms only by epithelial cells (e.g., as a
result of apoptosis), we provide here the first evidence for a
release of full-length CK19 by viable epithelial tumor cells.
Control experiments were performed to demonstrate that this
release was an active process and not simply the conse-
quence of apoptosis. In addition, our clinical follow-up results
– although still preliminary – suggest that viable tumor cells
secreting CK19 may contribute to metastatic progression.
By using the EPISPOT on different breast and colon cancer
cell lines with monoclonal antibodies targeting different
epitopes of CK19, we showed that a significant fraction of
these cells release the intact full-length CK19. As immunos-
pots are the protein fingerprints left only by the viable RCs, a
cell culture is needed to accumulate a sufficient amount of the
released marker proteins. Thus, dying cells that do not secrete
adequate amounts of protein are not detected, as previously
described [13,24,25]. The full-length nature of the released
CK19 protein was confirmed by proteomic experiments on
MCF-7 breast cancer cell supernatants: (a) we did not detect
a specific tryptic fragment peptide, which should have been
detected if the CYFRA 21-1 were present in the culture super-
natant; and (b) we found a specific hydrophobic peptide
(amino acids 227 to 247), which can emerge only from the
intact insoluble CK19 protein.
By using different combinations of dual-fluorescent EPISPOT,
immunocytochemical analyses and cycloheximide, Brefeldin A
or vincristine cell-incubation, we obtained the first evidence
that the release of the intact full-length CK19 protein might be
an active process, probably mediated by vacuoles or vesicles
but using another protein-transport pathway than that
between the classic endoplasmic reticulum to the Golgi appa-
ratus. The precise mechanism, however, remains to be eluci-
dated. Keratin-like antigens can be released during cell
invasion [26], and ultrastructural studies indicated an associa-
tion of keratin proteins with secretory granules [27] and mucin
droplets [28]. However, the CK19 molecule lacks a secretory
leader and hydrophobic membrane-translocation sequence.
Moreover, it has no precursor [29], and it has never been
located in the endoplasmic reticulum and Golgi apparatus. A
possible mechanism might be blebbing of proteins of the cyto-
plasm surrounded by plasma membrane (like viral budding
[30]) or the release through exosomes known to contain
cytoskeletal proteins and to be involved in metastasis [31].
In a first attempt to unravel whether the release of CK19 has a
biologic function in tumor progression, we applied the CK19-
EPISPOT to detect with a high sensitivity viable cells releasing
CK19 in the BM of breast cancer patients. The consistent neg-
ative findings in samples from patients without carcinoma sup-
ported the assumption that CK19-RCs appear to be DTCs.
CK19-RCs were frequently found in the BM of breast cancer
patients, and the number of CK19-RCs was correlated with
the disease stage. This observation is consistent with the fact
that BM is the most prominent distant site for metastatic pro-
gression in breast cancer [7]. Most important, our clinical fol-
low-up data suggest, for the first time, that the release of CK19
seems to be important for the occurrence (M0 patients) or pro-
gression (M1 patients) of metastasis in breast cancer patients.
Although the biologic role of CK19 release remains to be elu-
cidated, it might be noteworthy that another cytokeratin (kera-
tin 17) was recently implicated in epithelial cell growth
regulation [32]. Moreover, Ding et al. [33] showed that overex-
pression of CK19 in hepatocellular carcinoma cells is related
to metastatic behavior.
The assumption that not all DTCs are relevant to metastatic
progression was emphasized by the present observation that,
in contrast to CK19-RCs, DTCs releasing MUC1 had no prog-
nostic impact. However, the number of patients analyzed in our
study is far too small to exclude that MUC1-expressing cells
might have clinical relevance in certain subsets of breast can-
Table 4
Multivariate hazard ratios for death from breast cancer
Variable Hazard ratio (95% CI) P value
CK19-RC 4.71 (1.78–12.52) 0.0019
MUC1-RC 0.44 (0.18–1.07) 0.0710
ER status 0.45 (0.20–1.01) 0.0528
TNM stage 1.92 (0.92–3.99) 0.0830
CI = confidence interval; RC = releasing cell; ER = estrogen 
receptor.Available online http://breast-cancer-research.com/content/11/3/R39
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cer [34]. Nevertheless, our results indicate that DTCs with dif-
ferent phenotypes appear to have a heterogeneous potential
to contribute to metastatic relapse, which is consistent with
previous reports on the expression of the HER2 oncogene
[35] and the urokinase-type plasminogen-activator receptor
[36,37] on DTCs.
Although we cannot exclude the possibility that CK19 release
is only a marker for the detection of DTCs, we propose that
DTCs with the CK19+/MUC1- phenotype might have a partic-
ular biologic potential. This assumption also is supported by
the findings of Gudjonsson et al. [8], who reported that
CK19+/MUC1- cells in the human breast may have stem cell-
like properties. These data are consistent with a report from
Max Wicha's group [9] on mouse mammary cells, which
showed that CK19 might be a putative stem-cell marker and
the findings of Peterson et al. [10] indicating CK19 as a
marker of breast cancer progenitors.
Conclusions
In conclusion, our present data suggest a potential role of
CK19 release as an indicator of aggressive behavior of dis-
seminated breast cancer cells. Besides further investigation of
the underlying mechanism, larger studies are now required to
evaluate whether the CK19-EPISPOT will provide more help-
ful clinical information than the current immunocytochemical or
RT-PCR-based DTC detection assays [38]. In addition, the
EPISPOT can be applied to the detection and characterization
of circulating tumor cells in the peripheral blood, an application
that has generated substantial interest over the past years
[23,39].
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